We are live on
!
Find out more
AVM
Arch Venture Management Portfolio holdings
AUM
$677M
1-Year Est. Return
322.07%
This Fund
S&P 500
1 Year Est. Return
+322.07%
AUM
$677M
AUM Growth
+$25.4M
(+3.9%)
Holding
10
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MAZE
1
Maze Therapeutics
MAZE
$1.32B
| $123M | 18.16% |
4,120,053
|
|
||
|
RAPP
2
Rapport Therapeutics
RAPP
$1.83B
| $117M | 17.23% |
3,728,738
|
|
||
3
Vir Biotechnology
VIR
$1.46B
| $116M | 17.09% |
12,916,663
|
|
||
4
Erasca
ERAS
$4.37B
| $115M | 16.95% |
7,091,557
-3,963,997
|
|
||
5
Beam Therapeutics
BEAM
$3.15B
| $108M | 15.98% |
4,540,132
|
|
||
6
Lyell Immunopharma
LYEL
$318M
| $65.1M | 9.62% |
3,247,162
+488,090
|
|
||
|
GENB
7
Generate Biomedicines
GENB
$1.72B
| $24.3M | 3.59% |
+1,944,426
|
|
||
8
10x Genomics
TXG
$4.02B
| $4.62M | 0.68% |
217,834
-519,705
|
|
||
9
Gossamer Bio
GOSS
$83.8M
| $2.65M | 0.39% |
8,055,916
|
|
||
10
Q32 Bio
QTTB
$217M
| $2.06M | 0.3% |
320,482
|
|